Table of contents
- Trial overview
- Condition and population studied
- Treatments being tested
- Trial phase and design
- What the trial measures
- What this means for patients
Trial overview
This clinical trial studied ZALFERMIN in people with alcohol-related liver disease, a liver condition linked to alcohol use.[1] The study was interventional, which means researchers assigned treatments and then compared outcomes.[1] It was a Phase 2 trial and was marked as completed.[1]
Condition and population studied
The trial focused on adults with alcohol-related liver disease.[1] The study data do not give more detailed entry rules, so the exact participation criteria are not fully listed here.[1] In simple terms, the study looked at people who already had liver problems related to alcohol use.[1]
Treatments being tested
The trial compared ZALFERMIN with other study treatments and with placebo, which is an inactive treatment used for comparison.[1] The listed interventions included cagrilintide, semaglutide, combinations of these drugs, placebo, and ZALFERMIN given by subcutaneous injection, meaning under the skin.[1] The study summary says the goal was to test these treatment options alone and in combination versus placebo for liver damage and function.[1]
Trial phase and design
This was a Phase 2 study, which is a mid-stage trial that looks more closely at whether a treatment may work and keeps checking safety.[1] The study type was interventional, so the research team actively assigned the study treatments instead of only observing people.[1] The enrollment was 287 people, showing a moderate-size trial group for this type of research.[1]
What the trial measures
The main outcome was the change in Enhanced Liver Fibrosis (ELF).[1] ELF is a blood test-based measure used to help estimate liver fibrosis, which means scarring in the liver.[1] By tracking this change, the study aimed to see whether the treatments could improve or affect liver damage and liver function.[1]
What this means for patients
For patients, this trial shows that ZALFERMIN is being explored as part of research for alcohol-related liver disease, not as a routine treatment described in this data.[1] The study looked at whether ZALFERMIN and related treatment combinations could help with liver injury compared with placebo.[1] Because the trial is completed, the next step would be to review the results to understand whether the treatment approach was helpful.[1]
